Artwork

Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.
Player FM - Aplicație Podcast
Treceți offline cu aplicația Player FM !

Ep. 475 Bariatric Embolization for Obesity Management with Dr Cliff Weiss

45:40
 
Distribuie
 

Manage episode 435164401 series 2658136
Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment.

---

CHECK OUT OUR SPONSOR

Reflow Medical

https://www.reflowmedical.com/

---

SYNPOSIS

Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration.

He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial.

---

TIMESTAMPS

00:00 - Introduction

03:21 - Early Research and Development of BAE

07:39 - Potential Role of BAE in Obesity Treatment

16:03 - Procedure Details

25:28 - Post-Procedure Care and Patient Management

28:06 - Insights from the BEAT Obesity Trial

33:38 - BEATLES Trial

37:38 - Combination Therapy for Obesity

---

RESOURCES

BEAT Obesity Trial:

https://pubs.rsna.org/doi/full/10.1148/radiol.2019182354

LC Bead/Bead Block:

https://www.bostonscientific.com/en-US/products/embolization/lc-bead.html

EmboSpheres:

https://www.merit.com/product/embosphere-microspheres/

EMBIO Trial:

https://bmjopen.bmj.com/content/13/9/e072327

BEATLES Trial:

https://www.jvir.org/article/S1051-0443(23)01155-7/fulltext

  continue reading

514 episoade

Artwork
iconDistribuie
 
Manage episode 435164401 series 2658136
Content provided by BackTable LLC. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BackTable LLC or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ro.player.fm/legal.

While GLP-1 agonists continue to gain popularity in the medical management of diabetes and obesity, Dr. Cliff Weiss is exploring bariatric arterial embolization (BAE) as an adjunctive therapy to help patients sustain weight loss. Dr. Weiss, the Director of IR Research at Johns Hopkins, joins the show to discuss the techniques and impacts of BAE for obesity treatment.

---

CHECK OUT OUR SPONSOR

Reflow Medical

https://www.reflowmedical.com/

---

SYNPOSIS

Dr. Weiss outlines his initial research interest in gastric embolization of the fundus to reduce ghrelin production. He began by studying the use of sclerosants for embolization but later shifted to using embolic spheres. BAE involves the targeted embolization of the left gastric artery, with or without the left gastroepiploic artery, using 300-500 micron embolic spheres. Dr. Weiss also employs a dilute mixture of spheres and a vasodilator to achieve distal arterial penetration.

He describes the role of BAE in conjunction with existing surgical and pharmaceutical treatments. According to his experience, patients undergoing BAE achieve maximum weight loss 6-9 months after the procedure and can maintain this weight when they follow up in a weight management clinic. Additionally, Dr. Weiss reviews data from BAE studies, including the BEAT Obesity Trial and the recent BEATLES Trial.

---

TIMESTAMPS

00:00 - Introduction

03:21 - Early Research and Development of BAE

07:39 - Potential Role of BAE in Obesity Treatment

16:03 - Procedure Details

25:28 - Post-Procedure Care and Patient Management

28:06 - Insights from the BEAT Obesity Trial

33:38 - BEATLES Trial

37:38 - Combination Therapy for Obesity

---

RESOURCES

BEAT Obesity Trial:

https://pubs.rsna.org/doi/full/10.1148/radiol.2019182354

LC Bead/Bead Block:

https://www.bostonscientific.com/en-US/products/embolization/lc-bead.html

EmboSpheres:

https://www.merit.com/product/embosphere-microspheres/

EMBIO Trial:

https://bmjopen.bmj.com/content/13/9/e072327

BEATLES Trial:

https://www.jvir.org/article/S1051-0443(23)01155-7/fulltext

  continue reading

514 episoade

Toate episoadele

×
 
Loading …

Bun venit la Player FM!

Player FM scanează web-ul pentru podcast-uri de înaltă calitate pentru a vă putea bucura acum. Este cea mai bună aplicație pentru podcast și funcționează pe Android, iPhone și pe web. Înscrieți-vă pentru a sincroniza abonamentele pe toate dispozitivele.

 

Ghid rapid de referință